Latest Breaking News On - Aldose reductase inhibitor - Page 6 : comparemela.com

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shoshana shendelmanMaeve conneightonAdvanz pharmaExchange commissionTherapeutics incUniversity of miamiThree phaseHigh unmet clinical needIncluding positive sorbitol reduction dataOngoing phaseSorbitol dehydrogenaseReport additional phaseAcross multiple programsPositive sorbitol reduction dataAldose reductase inhibitorGalactosemia kids

Applied Therapeutics Reports Third Quarter 2022 Financial Results

Applied Therapeutics Reports Third Quarter 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMaeve conneightonShoshana shendelmanExchange commissionTherapeutics incAmerican heart association scientific sessionsDiabetic cardiomyopathyHeart association scientificAldose reductaseFull enrollmentRegistrational phasePositive data trendGalactosemia kids pediatricGalactosemia kids phaseGalactosemia kidsAldose reductase inhibitor

Applied Therapeutics Reports Second Quarter 2022 Financial Results

12.08.2022 - Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high .

Maeve conneightonShoshana shendelmanExchange commissionTherapeutics incEuropean medicines agencyDiabetic cardiomyopathyOrphan medicinal product designationApplied therapeuticsMarketing authorization applicationGalactosemia kidsAldose reductase inhibitorPrivate securities litigation reform act

Applied Therapeutics, Inc Announces Pricing of $30 Million

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company.

United statesMaeve conneightonExchange commissionTherapeutics incSyndicate departmentAldose reductase inhibitorDiabetic cardiomyopathyPrivate securities litigation reform actNasdaq apltApplied therapeutics

Applied Therapeutics, Inc Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

Applied Therapeutics, Inc Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesMaeve conneightonExchange commissionTherapeutics incSyndicate departmentApplied therapeuticsAldose reductase inhibitorDiabetic cardiomyopathyPrivate securities litigation reform act